GSK plc (GSK) Stock Price & How to Invest

GSK plc is a UK-headquartered global biopharma company, one of the largest by revenue, focused on preventing and treating disease through vaccines, specialty medicines, and general medicines. It reorganized in 2022 when it spun off its consumer health arm as Haleon, leaving GSK as a pure biopharma business. Its most durable franchises are vaccines, led by the shingles vaccine Shingrix and the newer RSV vaccine Arexvy, and HIV, which it manages largely through the ViiV Healthcare joint venture with a shift toward long-acting injectable regimens. It also has growing positions in respiratory, immunology and inflammation, and oncology.

The business model combines steady cash generation from vaccines and HIV with heavy reinvestment in R&D to build newer specialty and oncology assets. Vaccines are attractive because they carry high margins and real-world efficacy data (Shingrix efficacy was around 90% in trials) that support pricing and repeat demand across developed and emerging markets.

The mid-2026 investment picture is one of steady execution against a lower valuation than several US large-cap pharma peers. Vaccine demand and respiratory growth have supported revenue, and analysts have pointed to vaccines and new approvals (including in asthma and oncology) as reasons the pharma story keeps moving. The counterweights are patent expiries on maturing products, a historically less dynamic pipeline than some rivals, and litigation overhangs such as the long-running Zantac cases. This makes GSK more of a value-and-yield style pharma holding than a high-growth name, and its rerating depends heavily on pipeline delivery.

The central risk is the patent cliff and pipeline dependence: maturing products face generic and biosimilar competition, and the longer-term case relies on newer launches replacing that revenue, which is never guaranteed in drug development. GSK has been viewed as having a historically less dynamic pipeline than some rivals, so R&D setbacks or trial failures would weigh heavily. Litigation is another overhang, notably the long-running Zantac cases where GSK has been named among defendants, which can create headline and financial uncertainty. As an ADR of a UK company, US investors also carry currency risk between the pound and the dollar, plus exposure to UK and EU drug-pricing policy and US pricing reform. Vaccine demand can be lumpy year to year, and competition from Pfizer, Merck, and AstraZeneca across vaccines, HIV, and oncology is intense.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see GSK plc's investor relations page or your broker.

• Revenue (TTM): approximately £31 to £32 billion, with vaccines, HIV, and specialty medicines the main contributors
• Operating margin: reported around the mid-to-high 20s percent on an adjusted basis, typical of large-cap pharma
• EPS: adjusted earnings per share reported in roughly the mid-single-digit dollars per ADR; verify the latest figure live
• Market cap: approximately $105 to $110 billion (ADR traded around the low $50s in early 2026)
• Forward P/E: roughly high-single-digit to low-double-digit, generally below several US large-cap pharma peers
• Analyst view: mixed to modestly constructive, with some upgrades citing vaccine-driven revenue and new approvals; targets vary by house

These figures are approximate, tied to the asOf date, and reported in a mix of pounds and dollars because GSK is a UK company trading as a US ADR, so verify live numbers before acting. GSK's lower multiple reflects slower growth and pipeline and litigation overhangs rather than a distressed balance sheet. The stock tends to behave like a value-and-income pharma holding, so the multiple matters less than whether new launches can offset patent expiries over time.

There are three common ways to get GSK exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so GSK sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where GSK fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

GSK pairs durable, high-margin vaccines and HIV cash flows with a rebuilt specialty and oncology pipeline, trading at a lower multiple than some large-cap pharma peers. The key question is whether new launches can offset patent expiries and lingering litigation overhangs fast enough to reaccelerate growth.